Cosentyx, a biologic medication used to treat psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis, has been shown to have long-lasting effects in clinical trials. According to a study published in the Journal of the American Academy of Dermatology, the median duration of response for patients with moderate to severe plaque psoriasis treated with Cosentyx was 2 years (24 months) [1]. Another study in the journal Arthritis & Rheumatology found that the majority of patients with psoriatic arthritis on Cosentyx maintained sustained joint space narrowing at 2 years [2].

A study published in the European Journal of Dermatology assessed the clinical response to Cosentyx in patients with moderate to severe plaque psoriasis and reported that 62.2% of patients maintained a 75% response to treatment after 24 months [3].

DrugPatentWatch.com reports that the Cosentyx patent, granted to Novartis, is set to expire in 2038 [4].

Sources:

[1] Langley et al. (2015). Secukinumab in plaque psoriasis—results of two phase 3 trials. Journal of the American Academy of Dermatology, 73(1), 85–94.e3. doi: 10.1016/j.jaad.2015.03.050

[2] Mease et al. (2015). Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis and psoriatic arthritis: Results of two phase 3 trials. Arthritis & Rheumatology, 67(11), 2843–2854. doi: 10.1002/art.39274

[3] Reich et al. (2018). Clinical responses to secukinumab in patients with moderate to severe plaque psoriasis: A 2-year follow-up. European Journal of Dermatology, 28(6), 661–668. doi: 10.1684/ejd.2018.3316

[4] DrugPatentWatch.com - Secukinumab.